Skip to main content

SHINE Medical secures $50M in additional funding for radioisotope production facility in Janesville

SHINE says it also will commercialize Lu-177, a therapeutic isotope currently used to treat neuroendocrine cancers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.